Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model

Table 3 Outcomes for screening, screening + vaccination (base case) for Chilean girls aged 11 years (undiscounted)

	N	n (%)^a
	No vaccination^b	HPV-16/18 vaccine^c	HPV-6/11/16/18 vaccine^c
Incident cases of genital warts	4813	4813 (100%)	1445 (30.0%)
Incident cases of CIN1	6249	3100 (49.6%)	2727 (43.6%)
Incident cases of CIN23	1754	691 (39.4% )	881 (50.2% )
Incident cases of cervical cancer	1370	198 (14.5%)	300 (21.9 %)
Incident cases of cervical cancer deaths	722	104 (14.4%)	158 (21.9 %)
LY	8725602	8738561	8737415
QALY	8723071	8738044	8736841
Total treatment and follow-up related costs^d	94208827	39776161 (42.2%)	43413777 (46.1%)
Screening	24878067	25085155 (100.8%)	25102940 (100.9%)
CIN1 treatment	10223106	5071376 (49.6%)	4461609 (43.6%)
CIN23 treatment	2869923	1130504 (39.4%)	1441268 (50.2%)
Genital warts	396244	396334 (100.0%)	118954 (30.0%)
Cervical cancer	55841487	8092792 (14.5 %)	12289006 (22.0 %)
Vaccination costs^d		7044117	7044117
Net total costs^d	94208827	46820278 (49.7%)	50457894 (53.6%)

^aPercentage of no vaccination scenario; ^bScreening alone scenario; ^cScreening plus vaccination scenarios; ^dAll costs are presented in 2010 United States dollars.
Note: CIN: cervical intraepithelial neoplasia; LY: life years; QALY: quality-adjusted life years.

ISSN: 1471-2458